Related Experiment Video
Updated: Nov 8, 2025
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Development and application of therapeutic antibodies against COVID-19
Lin Ning1, Hamza B Abagna2,3, Qianhu Jiang2,3
1School of Healthcare Technology, Chengdu Neusoft University, Sichuan, China.
Abstract:
The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, i.e., convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems and challenges, suggesting new strategies and solutions.
Insights
Therapeutic antibodies targeting SARS-CoV-2 are crucial for COVID-19 treatment. This review covers antibody development progress, applications, and challenges, offering new strategies for this global health crisis.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, remains a significant global health threat.
- Genomic and proteomic studies have identified numerous viral and host targets for therapeutic development.
- Antibody-based therapies have emerged as a critical component of COVID-19 treatment strategies.
Purpose of the Study:
- To review the progress in the development and application of therapeutic antibodies for COVID-19.
- To discuss the challenges and limitations associated with current antibody therapies.
- To propose novel strategies and solutions for advancing COVID-19 antibody treatment.
Main Methods:
- Comprehensive literature review of preclinical and clinical studies on COVID-19 therapeutic antibodies.
- Analysis of data on antibody formats including polyclonal, monoclonal, and cocktail antibodies.
- Examination of regulatory approvals and ongoing clinical trials for antibody therapies.
Main Results:
- Hundreds of antibodies have been developed, with several authorized for emergency use by the FDA, including convalescent plasma, bamlanivimab, REGN-Cov2, and a bamlanivimab/etesevimab cocktail.
- Therapeutic antibody therapies represent a dynamic and vital area of COVID-19 research and clinical practice.
- Numerous clinical trials are actively investigating the efficacy and safety of various antibody treatments worldwide.
Conclusions:
- Therapeutic antibodies have shown significant promise in combating COVID-19, with ongoing research addressing existing challenges.
- Continued innovation in antibody development and strategic application is essential for managing the pandemic.
- Future efforts should focus on overcoming hurdles in antibody therapy to enhance global health outcomes.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
01:29Microorganisms in Medicine and Therapeutics
00:42Cross-reactivity